Welcome to our dedicated page for Longeveron news (Ticker: LGVN), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (NASDAQ: LGVN) is a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions. Its news flow centers on the progress of its lead investigational product, laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors.
On this page, readers can follow LGVN news related to key clinical programs in hypoplastic left heart syndrome (HLHS), mild Alzheimer’s disease, pediatric dilated cardiomyopathy (DCM), and aging-related frailty. Company announcements highlight milestones such as pivotal Phase 2b trial enrollment in HLHS (ELPIS II), Phase 2a data in Alzheimer’s disease from the CLEAR MIND study, and regulatory interactions including FDA designations like Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT).
Longeveron’s news also covers intellectual property developments, including U.S. and Canadian patents for the use of its proprietary mesenchymal stem cells in aging-related frailty, non-ischemic dilated cardiomyopathy, and female sexual dysfunction. Scientific and medical conference activity, such as poster presentations at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and participation in cardiovascular clinical trial forums, provides additional insight into how the company positions laromestrocel within neurodegenerative and cardiovascular research.
Investors and observers can use this LGVN news feed to track clinical trial updates, patent grants, financing transactions disclosed in press releases, and other corporate developments that Longeveron reports through GlobeNewswire and SEC-related communications.
Longeveron (NASDAQ: LGVN) was selected as a StartUp Health Alzheimer’s & Brain Health Moonshot company and will participate in StartUp Health Apollo House during JPM Healthcare Week in January 2026. Apollo House is a founders-and-funders networking summit focused on Health Moonshots for Alzheimer’s, Parkinson’s and related conditions, supported by champions including the Alzheimer’s Drug Discovery Foundation and Gates Ventures.
Longeveron said it will host meetings with institutional investors and potential partners during the week; investors may request meetings by contacting info@longeveron.com.
Longeveron (NASDAQ: LGVN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,496,316 on Dec. 17, 2025 for methods of administering isolated allogeneic mesenchymal stem cells (MSCs) to treat female sexual dysfunction and improve sexual quality of life.
The patent provides U.S. rights through 2038 with potential patent term or regulatory exclusivity extensions. The company noted female sexual dysfunction affects up to 46% of women and said the patent expands its aging-focused intellectual property portfolio. Longeveron anticipates pursuing licensing or partnering opportunities for development and commercialization of the therapy.
Longeveron (NASDAQ: LGVN) announced that its Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will speak at the Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., December 8-10, 2025.
The executives will join multiple panel discussions on cell therapy for heart failure, including delivery routes, cell types (mesenchymal stem cell therapy for dilated cardiomyopathy referencing POSEIDON and PATH AHEAD), and multi‑stakeholder debate on streamlining cell therapy innovation while maintaining evidence standards.
Longeveron (NASDAQ: LGVN) announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3043594 covering methods to administer its proprietary mesenchymal stem cell therapy laromestrocel (LOMECEL-B) for treatment of aging-related frailty with inflammaging and for non-ischemic dilated cardiomyopathy (NIDCM).
The patent provides Longeveron with rights in Canada through 2037. The company cites prior Phase 1 and 2 studies that delivered positive initial results in aging-related frailty, including designed improvements in the six-minute walk test and physical functioning. The release emphasizes inflammaging links to frailty and notes MSCs have shown favorable changes in immunologic markers in vivo.
Longeveron (NASDAQ: LGVN) presented Phase 2 CLEAR MIND MRI biomarker data at CTAD 2025 showing that laromestrocel treatment was associated with reduced MRI-measured neuroinflammation (free water) versus placebo across multiple brain regions, most notably the hippocampus and temporal lobe.
Key trial signals include hippocampal free water reductions with dose response (Group 4: p=0.004, N=8; Group 3: p=0.037, N=8), additional regional p-values at week 39, correlated hippocampal volume preservation, clinical benefit, and prior RMAT and fast-track designations from FDA.
Longeveron (NASDAQ: LGVN) announced its submission titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” was selected for a poster at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025), held Dec 1–4, 2025 in San Diego.
The poster appears in Poster Session 1 (Section 11: New Therapies and Clinical Trials) with scheduled viewing from Dec 1, 3:00 p.m. PT to Dec 2, 5:30 p.m. PT. The announcement summarizes laromestrocel (Lomecel-B) as a mesenchymal stem cell product proposed to have immunomodulatory and regenerative mechanisms relevant to Alzheimer’s research.
Longeveron (NASDAQ: LGVN) announced the U.S. Patent and Trademark Office granted U.S. Patent No. 12,465,620 for a method of treating aging-related frailty with inflammaging using human mesenchymal stem cells. The patent provides U.S. rights through 2038, with potential for patent-term or regulatory exclusivity extensions.
The company’s lead MSC therapy, laromestrocel, has delivered positive initial results across two clinical trials and prior Phase 1 and 2 studies were designed to show improvements in the six-minute walk test and physical functioning in aging-related frailty patients. Aging-related frailty is described as a multisystem syndrome linked to inflammaging.
Longeveron (NASDAQ: LGVN) reported Q3 2025 results and a business update on Nov 4, 2025. Key clinical milestones include a fully enrolled pivotal Phase 2b trial ELPIS II for laromestrocel in Hypoplastic Left Heart Syndrome (HLHS) with top-line results expected in Q3 2026 and a potential BLA submission in 2027 if results support efficacy. Laromestrocel has multiple regulatory designations for HLHS and Alzheimer’s disease and an FDA‑accepted IND for pediatric dilated cardiomyopathy with a planned pivotal Phase 2 in 2026, subject to financing.
Q3 financials: nine‑month revenue down to $0.8M, net loss $17.3M, and cash of $9.2M as of Sep 30, 2025; cash runway guided into late Q1 2026 with ATM access and prior August financing.
Longeveron (NASDAQ: LGVN) will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. Dial-in: 1.877.407.0789 with Conference ID 13755997. A replay of the webcast will be available in the Events & Presentations section of the company website following the call.
Longeveron (NASDAQ: LGVN) announced that Co‑founder and Chief Science Officer Dr. Joshua Hare was interviewed on NPR’s BioTech Nation about hypoplastic left heart syndrome (HLHS) and Longeveron’s investigational stem cell therapy, laromestrocel. The company said its pivotal Phase 2b trial ELPIS II is fully enrolled and top‑line results are anticipated in Q3 2026. ELPIS II follows ELPIS I, where treated children experienced 100% transplant‑free survival to five years versus an approximate 20% mortality rate from historical controls. The trial is conducted with NHLBI via NIH grants. The FDA previously designated laromestrocel as Orphan Drug, Fast Track, and Rare Pediatric Disease, and in August 2024 confirmed ELPIS II as a pivotal trial that could support a BLA if efficacy is demonstrated.
FAQ
What is the current stock price of Longeveron (LGVN)?
What is the market cap of Longeveron (LGVN)?
